The effects of mepolizumab on peripheral circulation and neurological symptoms in eosinophilic granulomatosis with polyangiitis (EGPA) patients

Allergol Int. 2021 Jan;70(1):148-149. doi: 10.1016/j.alit.2020.08.005. Epub 2020 Sep 20.

Affiliations

¹ Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan. Electronic address: kitamura.noboru@nihon-u.ac.jp.
² Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

PMID: 32967778
DOI: 10.1016/j.alit.2020.08.005

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Blood Circulation / drug effects
C-Reactive Protein / analysis
Eosinophilia / blood
Eosinophilia / drug therapy*
Eosinophilia / immunology
Eosinophilia / physiopathology
Eosinophils / immunology
Female
Granulomatosis with Polyangiitis / blood
Granulomatosis with Polyangiitis / drug therapy*
Granulomatosis with Polyangiitis / immunology
Granulomatosis with Polyangiitis / physiopathology
Humans
Immunoglobulin E / blood
Interleukin-5 / antagonists & inhibitors
Leukocyte Count
Male
Middle Aged
Nitric Oxide / immunology
Retrospective Studies
Sural Nerve / drug effects
Sural Nerve / physiology

Substances

Antibodies, Monoclonal, Humanized
Interleukin-5
Nitric Oxide
Immunoglobulin E
C-Reactive Protein
mepolizumab